Bellicum Pharmaceuticals Inc (BLCM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -16,181 | -15,418 | -8,066 | -24,973 | -18,776 |
| Depreciation Amortization | 7 | 5 | 3 | 11 | 9 |
| Accounts receivable | -15 | N/A | -8 | 205 | -795 |
| Accounts payable and accrued liabilities | 40 | -14 | 740 | 396 | 624 |
| Other Working Capital | -207 | 658 | 1,648 | -1,466 | -1,173 |
| Other Operating Activity | 417 | 346 | -747 | 44 | 1,239 |
| Operating Cash Flow | $-15,939 | $-14,423 | $-6,430 | $-25,783 | $-18,872 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 11 | -4 | -5 | -21 | -14 |
| Investing Cash Flow | $11 | $-4 | $-5 | $-21 | $-14 |
| Cash Flows From Financing Activities | |||||
| Financing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Exchange Rate Effect | 0 | N/A | N/A | -16 | -15 |
| Beginning Cash Position | 21,837 | 21,837 | 21,837 | 47,657 | 47,657 |
| End Cash Position | 5,909 | 7,410 | 15,402 | 21,837 | 28,756 |
| Net Cash Flow | $-15,928 | $-14,427 | $-6,435 | $-25,820 | $-18,901 |
| Free Cash Flow | |||||
| Operating Cash Flow | -15,939 | -14,423 | -6,430 | -25,783 | -18,872 |
| Capital Expenditure | -4 | -4 | -5 | -21 | -14 |
| Free Cash Flow | -15,943 | -14,427 | -6,435 | -25,804 | -18,886 |